Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMVP Health Care Tzield Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentMVP Health CarePolicy 110

    Teplizumab-mzwv (Tzield) Coverage Criteria

    Customize your policy alerts

    Sign up for MVP Health Care Policy 110 alerts

    Get alerted when Policy 110 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and medical-benefit coverage for intravenous teplizumab-mzwv (Tzield) for Medicare Part B members age 8 years and older with stage 2 type 1 diabetes who meet specified clinical, laboratory, dosing, and infection-related requirements.

    Policy Summary
    PayerMVP Health Care
    PolicyTeplizumab-mzwv (Tzield) Coverage Criteria
    Policy CodePolicy 110
    Change TypeNo material clinical or coverage change
    Effective DateApr 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for teplizumab-mzwv (Tzield) under the medical benefit.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    J9381HCPCS code requiring prior authorization
    Stage 2 type 1 diabetesCovered clinical indication
    8+ yearsMinimum member age
    14 infusionsInitial approval course

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2 months
    Maximum initial course period
    Not coveredAdditional courses and replacement product

    Coverage Criteria

    Teplizumab is not covered when dosing, age, or frequency falls outside FDA-approved package labeling; when the member has type 2 diabetes; or when the member has an active serious infection, a chronic infection other than a localized skin infection, or laboratory or clinical evidence of acute Epstein-Barr virus (EBV) or cytomegalovirus (CMV) infection.

    Coverage is limited to the initial course of 14 consecutive infusions within two months. Additional courses are not covered, and requests for replacement product due to loss or damage are not covered.

    Clinical and Coding Requirements

    Drugs Requiring Prior Authorization under the medical benefitHCPCSCovered
    J9381Tzield (teplizumab-mzwv)
    Qualifying pancreatic islet cell autoantibodies
    Minimum antibodiesAt least two positive pancreatic islet cell autoantibodies
    Confirmation periodConfirmed within the past 6 months
    Qualifying antibodiesGAD65, insulin autoantibody, IA-2 autoantibody, zinc transporter 8 autoantibody, or islet cell autoantibody
    Fasting glucose
    Qualifying range110 to 125 mg/dL
    Test typeFasting glucose level
    Clinical findingQualifies as dysglycemia without overt hyperglycemia
    Two-hour postprandial glucose
    Minimum levelAt least 140 mg/dL
    Maximum levelLess than 200 mg/dL
    Test typeTwo-hour postprandial plasma glucose level
    Intervening postprandial glucose
    Qualifying thresholdGreater than 200 mg/dL
    Testing timesAt 30, 60, or 90 minutes
    Required frequencyOn two occasions within the past 60 days
    Hemoglobin
    Minimum levelGreater than 10 g/dL
    Laboratory measureHemoglobin
    DocumentationConfirmed by complete blood count
    Lymphocyte count
    Minimum levelGreater than 1,000 lymphocytes/mcL
    Laboratory measureLymphocyte count
    DocumentationConfirmed by complete blood count
    Platelet count
    Minimum levelGreater than 150,000 platelets/mcL
    Laboratory measurePlatelet count
    DocumentationConfirmed by complete blood count
    Absolute neutrophil count
    Minimum levelGreater than 1,500 neutrophils/mcL
    Laboratory measureAbsolute neutrophil count
    DocumentationConfirmed by complete blood count
    ALT and AST
    ALT limitNot greater than 2 times the upper limit of normal
    AST limitNot greater than 2 times the upper limit of normal
    Combined requirementNeither ALT nor AST may exceed 2 times the upper limit of normal
    Bilirubin
    Maximum permitted levelNot greater than 1.5 times the upper limit of normal
    Laboratory measureBilirubin concentration
    DocumentationLiver-function laboratory results must confirm the limit is met

    Prior Authorization and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for teplizumab-mzwv (J9381) under the medical benefit. Submit the clinical documentation supporting the indication, eligibility, dosing, and safety requirements before treatment.

    • Drug: J9381 Tzield (teplizumab-mzwv).
    • Authorization applies to the requested medical-benefit course and requires documentation of all applicable coverage criteria, including specialist involvement, stage 2 type 1 diabetes, laboratory confirmation, and FDA-labeled dosing.
    Documentation Required

    Specialist and Stage 2 Diabetes Documentation

    The drug must be prescribed by, or administered in consultation with, an endocrinologist. Document stage 2 type 1 diabetes and confirm that the member does not have type 2 diabetes.

    • Diagnosis must be stage 2 type 1 diabetes.

    Background

    Tzield (teplizumab-mzwv) is an intravenously administered anti-CD3 antibody that binds certain immune system cells and moderates the immune response. It is intended to delay progression to stage 3 type 1 diabetes in adults and pediatric members age 8 years and older with stage 2 type 1 diabetes. Type 1 diabetes is an autoimmune disease caused by an inability to produce insulin and generally requires insulin replacement.

    Definitions

    Stage 2 type 1 diabetes
    ConditionStage 2 type 1 diabetes
    AutoantibodiesMultiple pancreatic islet autoantibodies
    Glycemic findingDysglycemia without overt hyperglycemia
    Dysglycemia
    Fasting glucose110 to 125 mg/dL
    Two-hour postprandial glucoseAt least 140 mg/dL and less than 200 mg/dL
    Intervening postprandial glucoseGreater than 200 mg/dL at 30, 60, or 90 minutes on two occasions within the past 60 days

    Initial Approval Criteria

    Initial approval criteria

    Initial coverage requires ALL of the following criteria.

    Initial approval requirements

    • Specialist and indication

      • Qualifying autoantibodies: At least two positive pancreatic islet cell autoantibodies are confirmed within the past six months.2 or more positive antibodies within 6 months

        Qualifying antibodies include GAD65, insulin autoantibody, IA-2 autoantibody, zinc transporter 8 autoantibody, or islet cell autoantibody.

      • Qualifying dysglycemia: An oral glucose tolerance test demonstrates dysglycemia without overt hyperglycemia.Fasting glucose 110-125 mg/dL; or 2-hour postprandial glucose >=140 and <200 mg/dL; or 30-, 60-, or 90-minute postprandial glucose >200 mg/dL on two occasions within the past 60 days

    Continuation and Additional Courses

    No additional courses

    Continuation or additional courses are not covered.

    Noncovered additional therapy: Additional courses after the initial course of 14 consecutive infusions within two months are not covered.Initial course limited to 14 consecutive infusions within 2 months

    Quantity Limits

    Teplizumab-mzwv (Tzield)
    MedicationTeplizumab-mzwv (Tzield)
    Course limit14 consecutive infusions
    Administration periodWithin two months
    Policy Summary
    PayerMVP Health Care
    PolicyTeplizumab-mzwv (Tzield) Coverage Criteria
    Policy CodePolicy 110
    Change TypeNo material clinical or coverage change
    Effective DateApr 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for teplizumab-mzwv (Tzield) under the medical benefit.
    SourceLink
    On This Page
    Coverage CriteriaClinical and Coding RequirementsPrior Authorization and DocumentationBackgroundDefinitionsInitial Approval CriteriaContinuation and Additional CoursesQuantity Limits
  1. Document the qualifying dysglycemia and pancreatic islet autoantibody results described in the diagnostic requirements.
  2. Members with a diagnosis of type 2 diabetes are not eligible for coverage.
  3. Documentation Required

    Diagnostic and Laboratory Documentation

    Submit diagnostic and laboratory documentation supporting eligibility, including qualifying antibody confirmation, oral glucose tolerance testing, blood counts, and hepatic laboratory results.

    • At least two positive pancreatic islet cell autoantibodies must be confirmed within the past 6 months: GAD-65, insulin autoantibody, IA-2, zinc transporter 8, or islet cell autoantibody.
    • Oral glucose tolerance testing must show dysglycemia without overt hyperglycemia: fasting glucose 110–125 mg/dL; 2-hour postprandial plasma glucose at least 140 mg/dL and less than 200 mg/dL; or an intervening 30-, 60-, or 90-minute postprandial glucose greater than 200 mg/dL on two occasions within the past 60 days.
    • Complete blood count must confirm hemoglobin greater than 10 g/dL, lymphocytes greater than 1,000/mcL, platelets greater than 150,000/mcL, and absolute neutrophils greater than 1,500/mcL.
    • Document ALT and AST concentrations no greater than 2 times the ULN and bilirubin no greater than 1.5 times the ULN.
    • Member must be 8 years of age or older.
    Denial Risk

    Exclusions and Infection-Related Denial Risks

    Coverage is denied when teplizumab is used outside FDA-approved package labeling or when specified diabetes or infection-related exclusions apply.

    • Not covered for dosing, age, and/or frequency outside the FDA-approved package labeling.
    • Not covered for a diagnosis of type 2 diabetes.
    • Not covered for members with an active serious infection or chronic infection, except localized skin infections.
    • Not covered when there is laboratory or clinical evidence of acute Epstein-Barr virus (EBV) or cytomegalovirus (CMV) infection.
    Billing Rule

    Initial Course and Replacement-Product Limits

    Initial approval is limited to one treatment course of 14 consecutive infusions within two months. Additional courses and replacement product requests are not covered.

    • Initial authorization: 14 consecutive infusions within two months.
    • Additional courses after the initial course are not covered.
    • Replacement requests for product that is lost or damaged are not covered.
  4. Required clinical and laboratory criteria

    • Complete blood count: Hemoglobin is greater than 10 g/dL, lymphocyte count is greater than 1,000 lymphocytes/mcL, platelet count is greater than 150,000 platelets/mcL, and absolute neutrophil count is greater than 1,500 neutrophils/mcL.
    • Liver function: Neither ALT nor AST is greater than 2 times the upper limit of normal, and bilirubin is not greater than 1.5 times the upper limit of normal.
  5. Age and dosing: The member is 8 years of age or older, and treatment is administered within FDA-approved package labeling as 14 consecutive infusions within two months.Age >=8 years; 14 consecutive infusions within 2 months
  6. Infection-related criteria: The member does not have an active serious infection or chronic infection other than a localized skin infection, and has no laboratory or clinical evidence of acute Epstein-Barr virus or cytomegalovirus infection.